Opyl Limited (ASX: OPL) executive director Damon Rasheed joins Proactive’s Tylah Tully to discuss the non-exclusive strategic partnership the company has entered with Alithia Life Sciences, a contract research organisation (CRO) specialising in clinical research solutions.
The collaboration aims to enhance clinical trial projects through the use of Opyl’s AI-powered analytics platform, TrialKey. Under this partnership, Alithia will integrate TrialKey’s AI-driven reports into its trial designs, benefiting from insights such as probability of success predictions, optimised trial strategies, and data validation. Opyl will receive over $5,000 AUD per report provided to Alithia as part of the agreement.
Both companies will collaborate on marketing activities to highlight the advantages of AI-driven solutions for clinical trials. The partnership can be terminated with 30 days’ notice, and both parties have agreed to maintain confidentiality of shared information. This collaboration reflects a shared commitment to improving clinical trial outcomes through data-backed approaches, aligning with Alithia’s focus on high-quality, efficient trial designs.
Tina Soulis, Alithia’s founder and director, expressed confidence in the partnership, while Saurabh Jain, executive chair of Opyl, highlighted its significance in supporting global clinical trials with AI-enhanced solutions.
#ProactiveInvestors #ASX #OpylLimited, #AI, #ClinicalTrials, #LifeSciences, #Partnership, #TrialKey, #Alithia, #Research, #DataDriven, #CRO, #HealthTech, #Innovation, #ClinicalResearch, #TechInMedicine, #AIinHealthcare, #Biopharma, #MedicalResearch, #ClinicalTrialDesign, #Healthcare, #PredictiveAnalytics
#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
